Biocon, NCSM partner to launch oncology support program
This collaboration combines Biocon's expertise in biosimilars with NCSM's community outreach to enhance cancer care accessibility, affordability in Malaysia;
Bengaluru: Biocon Biologics Limited, a fully integrated global biosimilars company, has partnered with the National Cancer Society of Malaysia (NCSM), a prominent not-for-profit cancer organization, to launch a Patient Assistance Program (PAP) in Malaysia aimed at improving access to affordable, high-quality biosimilars for underserved cancer patients in Malaysia.
Biocon Biologics will provide quality-assured biosimilars from its oncology portfolio, including Trastuzumab, Pegfilgrastim and Bevacizumab, to NCSM, which will manage patient enrolment and medicine supply as part of its healthcare services.
This collaboration combines Biocon's expertise in biosimilars with NCSM's community outreach to enhance cancer care accessibility and affordability in Malaysia.
The program will start with providing bTrastuzumab to cancer patients facing treatment delays due to budget constraints. The MoU was signed during the National Cancer Congress Malaysia 2025 event, emphasizing a commitment to improving patient-centric healthcare.
Ratish Trehan, Head of Commercial – Emerging Markets, Biocon Biologics, said, “Our partnership with the National Cancer Society of Malaysia marks a meaningful step forward in expanding access to high-quality oncology biosimilars for cancer patients in need. This collaboration, which combines our scientific expertise with NCSM’s strong community outreach and patient support network, aims to ease the treatment burden for underserved populations. Together, we hope to positively impact thousands of lives and strengthen Malaysia’s efforts to deliver inclusive, patient-centric healthcare.”
"Biocon Biologics aims to build on its previous success in expanding access to diabetes care in Malaysia, having served over 345,000 patients, and is now focusing on oncology through strategic partnerships like this," the company stated in its recent release.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.